{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T20:21:22Z","timestamp":1786911682636,"version":"build-2736575974"},"reference-count":65,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP22K16352"],"award-info":[{"award-number":["JP22K16352"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease entity characterized by systemic vasculitis positive for ANCAs, which often leads to severe organ damage such as diffuse bronchoalveolar hemorrhage and rapidly progressive glomerulonephritis. It is known that the incidence and characteristics of AAV vary depending on region, and differences in the peak age of onset, the ratio of positive rates of MPO-ANCA to PR3-ANCA, and occurrence rates of GPA and MPA may have resulted in different approaches to clinical practice. It may also be necessary to modify therapeutic strategies according to ethnic factors. Avacopan is a therapeutic option recently recommended for the management of AAV; however, the rate of severe liver injuries associated with avacopan was reported to be relatively high in the Japanese population. In this review, we introduce current globally recognized knowledge on the diagnosis and treatment of AAV, including a comparison of patient characteristics and clinical practice between Europe and Japan obtained from the recent literature.<\/jats:p>","DOI":"10.3390\/jcm14051724","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T04:58:17Z","timestamp":1741064297000},"page":"1724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current Diagnosis and Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Review Including a Comparison of Characteristics in Europe and Japan"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-3566","authenticated-orcid":false,"given":"Yoshiro","family":"Horai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Sasebo City General Hospital, Sasebo 857-8511, Japan"},{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kurushima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sasebo City General Hospital, Sasebo 857-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rukavina, K., Zlopasa, O., Vukovic Brinar, I., Dzubur, F., Anic, B., and Vujaklija Brajkovic, A. (2024). Critically III Patients with Newly Diagnosed Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Case Series and Literature Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195688"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Nakagawa, S., Totsuka, K., Kagami, S., and Nomoto, Y. (2024). Granulomatosis with Polyangiitis Discovered Because of Repeated Upper Eyelid Swelling. Medicina, 60.","DOI":"10.3390\/medicina60091555"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kaczmarczyk, M.S., Jurkiewicz, D., Niemczyk, S., and Rymarz, A. (2024). Aural Manifestations of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis\u2014Diagnosis, Symptoms, Treatment. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154298"},{"key":"ref_4","first-page":"7020595","article-title":"Microscopic Polyangiitis Initially Presumed to Be Endocarditis","volume":"2020","author":"Kaneko","year":"2020","journal-title":"Case Rep. Dent."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/rheumatology\/keac623","article-title":"Diagnosing and treating ANCA-associated vasculitis: An updated review for clinical practice","volume":"62","author":"Chevet","year":"2023","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sandino, J., and Morales, E. (2024). Role of Avacopan on Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226676"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/mr\/road081","article-title":"Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update\u2014Secondary publication","volume":"34","author":"Sada","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2018.1500437","article-title":"2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3899\/jrheum.130602","article-title":"Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan","volume":"41","author":"Furuta","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3899\/jrheum.160005","article-title":"Comparison of the Phenotype and Outcome of Granulomatosis with Polyangiitis Between UK and Japanese Cohorts","volume":"44","author":"Furuta","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/mrcr\/rxad019","article-title":"Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Kataoka","year":"2023","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan","volume":"63","author":"Kojima","year":"2024","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/mrcr\/rxae071","article-title":"Persistent Liver Injury Following Avacopan Discontinuation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Rare Case of Liver Biopsy in the Chronic Phase of Liver Injury","volume":"9","author":"Yamaguchi","year":"2025","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mori, K., Shirai, T., Mutoh, T., Inoue, J., Fujishima, F., Kubo, S., Watanabe, H., Sato, S., Narita, M., and Hoshi, Y. (2024). Drug-induced liver injury related to avacopan therapy. Rheumatology, keae689.","DOI":"10.1093\/rheumatology\/keae689"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Watanabe, R., and Hashimoto, M. (2023). Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185996"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keaa805","article-title":"Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"60","author":"Papo","year":"2021","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Habibi, M.A., Alesaeidi, S., Zahedi, M., Hakimi Rahmani, S., Piri, S.M., and Tavakolpour, S. (2022). The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Biology, 11.","DOI":"10.3390\/biology11121767"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2332\/allergolint.R-07-141","article-title":"ANCA-associated vasculitis: Diagnostic and therapeutic strategy","volume":"56","author":"Ozaki","year":"2007","journal-title":"Allergol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3109\/14397595.2014.982270","article-title":"Issues associated with the Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides: Reclassification of patients in the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides according to the MHLW criteria","volume":"25","author":"Sada","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/mr\/road017","article-title":"Validation of new ACR\/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"34","author":"Sada","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/mr\/road052","article-title":"Evaluation of Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody\u2013associated vasculitis compared to ACR\/EULAR 2022 classification criteria","volume":"34","author":"Sada","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Valero-Mart\u00ednez, C., Valenzuela, C., Baldivieso Ach\u00e1, J.P., Mart\u00ednez-Besteiro, E., Quiroga-Colina, P., Alfranca, A., Vicente-Rabaneda, E.F., Mu\u00f1iz, S.H., Casta\u00f1eda, S., and Garc\u00eda-Vicu\u00f1a, R. (2025). Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14010229"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100235","DOI":"10.1016\/j.jtauto.2024.100235","article-title":"Presentation and progression of MPO-ANCA interstitial lung disease","volume":"8","author":"Salvati","year":"2024","journal-title":"J. Transl. Autoimmun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/14397595.2019.1601855","article-title":"Association between preexisting lung involvements and the risk of diffuse alveolar hemorrhage in patients with microscopic polyangiitis: A multi-center retrospective cohort study","volume":"30","author":"Kida","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4550","article-title":"Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10238-024-01318-y","article-title":"Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA","volume":"24","author":"Gong","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/j.1756-185X.2010.01479.x","article-title":"Churg-Strauss syndrome: A retrospective study of 11 cases from a single center in Japan","volume":"13","author":"Horai","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e4871","DOI":"10.1097\/MD.0000000000004871","article-title":"Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and poor prognosis","volume":"95","author":"Fukui","year":"2016","journal-title":"Medicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/1756-185X.13422","article-title":"Antineutrophilic Cytoplasmic Antibody-Associated Vasculitis with and without Renal Involvement: C3 Contributes to Prognosis, but Renal Involvement Does Not","volume":"22","author":"Fukui","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Matsuda, S., Oe, K., Kotani, T., Okazaki, A., Kiboshi, T., Suzuka, T., Wada, Y., Shiba, H., Hata, K., and Shoda, T. (2023). Serum Complement C4 Levels Are a Useful Biomarker for Predicting End-Stage Renal Disease in Microscopic Polyangiitis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914436"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/03009742.2019.1695927","article-title":"Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: Analysis using sera from a nationwide prospective cohort study","volume":"49","author":"Fukui","year":"2020","journal-title":"Scand. J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2006.08.007","article-title":"The Overlap of Sj\u00f6gren\u2019s Syndrome with Other Systemic Autoimmune Diseases","volume":"36","author":"Font","year":"2007","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Whang, J.Y., Ha, J.W., Park, Y.-B., and Lee, S.-W. (2024). Clinical Significance of Overlap Syndrome of Histologically Confirmed Lupus Nephritis with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195831"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ha, J.W., Park, Y.-B., and Lee, S.-W. (2023). Overlap Syndrome Consisting of Polymyositis\/Dermatomyositis and ANCA-Associated Vasculitis According to the 2022 ACR\/EULAR Criteria for Vasculitis: A Korean Single-Centre Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216748"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/mr\/roac114","article-title":"Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis","volume":"35","author":"Watanabe","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of Reduced-Dose vs. High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/ard-2023-224343","article-title":"Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: Predefined 2-year follow-up study","volume":"83","author":"Furuta","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/ard-2023-224472","article-title":"Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: A propensity score analysis of the real-world nationwide database","volume":"83","author":"Ishikawa","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e2220925","DOI":"10.1001\/jamanetworkopen.2022.20925","article-title":"Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"5","author":"Thietart","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/mr\/roac118","article-title":"Concordance between practice and published evidence in the management of ANCA-associated vasculitis in Japan: A cross-sectional web-questionnaire survey","volume":"33","author":"Miyawaki","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: An international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Roccatello, D., Fenoglio, R., De Simone, E., and Sciascia, S. (2025). How We Treat ANCA-Associated Vasculitis: A Focus on the Maintenance Therapy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14010208"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.2169\/internalmedicine.3072-23","article-title":"Improved Hearing Impairment of Granulomatosis with Polyangiitis Treated with Rituximab and Avacopan without Glucocorticoids","volume":"63","author":"Okubo","year":"2024","journal-title":"Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ekir.2024.01.006","article-title":"Use of Avacopan in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL\/min per 1.73 m2","volume":"9","author":"Barr","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Jubashi, T., Tomokawa, T., Hara, K., Horai, Y., and Kawakami, A. (2024). Effectiveness and Safety of Avacopan as a Combination Therapy with Glucocorticoids or Monotherapy in Patients with Microscopic Polyangiitis. Intern. Med.","DOI":"10.2169\/internalmedicine.4389-24"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/mrcr\/rxae016","article-title":"Avacopan\u2019s potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis","volume":"8","author":"Taniguchi","year":"2024","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"rkae100","DOI":"10.1093\/rap\/rkae100","article-title":"Is it possible to use avacopan alone in the induction of remission in ANCA-associated vasculitis?","volume":"8","author":"Kubota","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/mr\/roac037","article-title":"Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study","volume":"33","author":"Harigai","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3899\/jrheum.2024-0340","article-title":"Absence of Glucocorticoids Concomitant with Avacopan and Subsequent Liver Injury in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"51","author":"Uchida","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:46:48Z","timestamp":1760028408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051724"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051724","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}